Adjuvant Chemotherapy for Completely Resected Non-Small Cell Lung Cancer.
- Author:
Sang We KIM
1
Author Information
1. Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. swkim@amc.seoul.kr
- Publication Type:Original Article
- Keywords:
Non-small cell lung cancer;
Adjuvant chemotherapy
- MeSH:
Carcinoma, Non-Small-Cell Lung*;
Chemotherapy, Adjuvant*;
Drug Therapy;
Humans;
Korea;
Lung Neoplasms
- From:Journal of Lung Cancer
2003;2(1):6-9
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Lung cancer is the number one cause of cancer-related deaths in Korea. Nonsmall cell lung cancers account for about 80% of these cases. Because the long term survival of patients after a complete resection is poor, postoperative adjuvant chemotherapy seems to be a very promising concept. However, studies on postoperative chemotherapy, to date, have been disappointing. Recently, the International Adjuvant Lung Cancer Trial (IALT) reported an absolute 5% statistically significant 5-year survival benefit (p<0.03). Further studies, which could select patients favored with adjuvant chemotherapy, are necessary.
